{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-166293","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2024-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.912827+00:00","generated_at":"2026-06-01T02:35:32.098180+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rani Therapeutics and ProGen partner on GLP-1/GLP-2 dual agonist PG-102 in RaniPill HC for weight management","bullets":["Parties will share development costs and operating profits/losses equally; Rani leads US, Canada, Europe, Australia development after Phase 2.","ProGen supplies PG-102; Rani manufactures final Product (Device + compound) worldwide.","Each party can opt-out anytime; continuing party pays low single to mid-single digit royalties on net sales post opt-out.","Priority regulatory markets include US, EU, UK, Canada, Australia, Japan, and South Korea.","Rani leads preclinical through Phase 1 globally; commercial rights split by assigned territories."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-166293","json":"https://secwatch.observer/filing/0001193125-24-166293.json","markdown":"https://secwatch.observer/filing/0001193125-24-166293.md","text":"https://secwatch.observer/filing/0001193125-24-166293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000119312524166293/0001193125-24-166293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000119312524166293/d841207d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:35:32.098180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}